In Vivo Imaging for Oncology Research: Applications and Workflows

Why Oncology Runs on In Vivo Imaging

Tumor biology happens in a living organism — in real blood vessels, immune systems and microenvironments. In vivo imaging lets you watch a tumor grow, spread and respond to therapy in the same animals across an entire study, replacing single-endpoint measurements with longitudinal data. That means fewer animals, tighter statistics and earlier readouts of drug efficacy. This guide summarises the main oncology applications, the imaging modes behind them, and a workflow you can adapt to your own tumor models.

Core Applications in Tumor Research

Application	What You Measure	Typical Readout
Tumor growth kinetics	Signal from implanted or spontaneous tumors over time	Growth curves, doubling time
Metastasis monitoring	Spread to distant organs	Lesion count, organ burden
Treatment response	Signal change under therapy vs control	Tumor growth inhibition
Cell tracking / biodistribution	Location of labelled cells or agents	Organ-specific accumulation
Rechallenge and relapse	Regrowth after treatment withdrawal	Time to relapse

Because each animal serves as its own baseline, longitudinal designs detect smaller treatment effects than endpoint studies — often with half the cohort size.

Choosing the Right Tumor Model

Match the model to the question before worrying about hardware. Subcutaneous implants are the easiest to monitor — signal is close to the surface, growth is fast, and drug-response readouts come quickly. Orthotopic models, with tumor cells implanted in the organ of origin, capture the clinically relevant microenvironment and are where longitudinal imaging adds the most value, since the tumor is otherwise hard to measure. Metastasis models (intravenous or spontaneous dissemination) rely almost entirely on imaging: bioluminescence detects deep lesions that palpation misses and lets you chart whole-body burden over time. In every case, a luciferase-labelled, stable-expressing cell line is the foundation — variable reporter expression masquerades as biological variance downstream.

Choosing an Imaging Mode

Mode	Reporter	Strengths	Watch-outs
Bioluminescence (BLI)	Luciferase-expressing tumor cells	Very low background; quantifiable; ideal for deep tumors	Requires luciferin injection; signal depends on cell ATP
Fluorescence (FLI)	Fluorescent proteins or dyes	No substrate needed; co-registration of multiple labels	Tissue autofluorescence and attenuation
Chemiluminescence (CLI)	Probe-driven light emission	Flexible labeling of probes	Lower signal; mode-dependent kinetics

For most subcutaneous and orthotopic tumor models, bioluminescence tumor imaging is the workhorse: background is near zero and signal tracks viable tumor cell number closely. Our comparison of bioluminescence vs fluorescence vs chemiluminescence walks through the trade-offs, and the in vivo imaging system buyer’s guide covers sensitivity and throughput considerations.

A Longitudinal Tumor-Imaging Workflow

• Model setup: implant luciferase-labelled tumor cells (subcutaneous for simple monitoring, orthotopic for clinically relevant microenvironment).
• Baseline imaging: once tumors are established, acquire a baseline image and define the ROI strategy for the whole study.
• Randomisation: group animals by baseline signal so treatment arms start balanced — a step many studies skip.
• Serial imaging: image weekly under identical settings (exposure, binning, field of view) and inject substrate with a consistent timing interval.
• Analysis: quantify total flux per ROI, plot growth curves per group, and compare tumor growth inhibition between arms.
• Validation: confirm final imaging readouts with ex vivo organ imaging and histology.

Designing a Robust Study

Keep every variable that affects photon counts constant across the study: substrate dose and route, anesthesia depth, body temperature during acquisition, and camera settings. Image all groups on the same day where possible, and include a mock-treated control arm. For a deeper treatment of turning raw images into defensible numbers, see our companion article on quantifying in vivo bioluminescence signals.

Oncology In Vivo Imaging FAQ

Can BLI quantify tumor burden in deep organs?
Yes — signal from orthotopic and metastatic models is measurable and correlates well with tumor cell number, though light attenuation through tissue means comparisons are strongest within the same site and posture.

How many animals can I image per session?
It depends on the field of view; a multianimal platform images several mice simultaneously, which shortens sessions and keeps timing consistent between animals.

Do I still need histology at the end?
Yes. Terminal histology validates what imaging measured and is expected by reviewers for efficacy claims.

Subcutaneous or orthotopic — which should I image first?
Start subcutaneous to establish the reporter line and dosing schedule, then move orthotopic once the biology and imaging protocol are stable.

The SHANGTONG LumiFluor AVIS

The SHANGTONG LumiFluor AVIS small-animal in vivo imaging system supports bioluminescence, fluorescence and chemiluminescence in one platform, with a high-sensitivity camera, multi-animal imaging and analysis software for longitudinal tumor studies. See the full Small Animal Imaging line for more.

This article is provided for informational purposes as part of the SHANGTONG Knowledge Library.